Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hadoux J
Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,
Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,
Introduction: The 2018 SEER data indicates EP-PD-NEC morphology (SC vs. nSC) may impact patient outcomes.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Zaninotto E
Authors: Zaninotto E, Frizziero M, Durand A, Taboada R, Luchini C,
Keywords: small cell neuroendocrine carcinoma, non small cell neuroendocrine carcinoma, predictive value,
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,
Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,
Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,
Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,
Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,